Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units

被引:196
作者
Molldrem, JJ [1 ]
Clave, E [1 ]
Jiang, YZ [1 ]
Mavroudis, D [1 ]
Raptis, A [1 ]
Hensel, N [1 ]
Agarwala, V [1 ]
Barrett, AJ [1 ]
机构
[1] NHLBI,BONE MARROW TRANSPLANTAT UNIT,HEMATOL BRANCH,NIH,BETHESDA,MD 20892
关键词
D O I
10.1182/blood.V90.7.2529.2529_2529_2534
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
We previously showed that a peptide (PR1) derived from the primary granule enzyme proteinase 3 induced peptide specific cytotoxic T lymphocytes (CTL) in a normal HLA-A2.1(+) individual. These CTL showed HLA-restricted cytotoxicity to myeloid leukemias (which overexpress proteinase 3). To further investigate their antileukemic potential, we studied the ability of PR1-specific CTL, derived from two HLA-A2.1(+) normal individuals, to inhibit colony-forming unit granulocyte-macrophage (CFU-GM) from normal and leukemic individuals. CTL from 20 day PR1 peptide-pulsed lymphocyte cultures showed 89% to 98% HLA-A2.1-restricted colony inhibition of chronic myeloid leukemia targets. Colony formation in normal HLA-A2.1(+) bone marrow or HLA-A2.1(-) CML cells was not inhibited. Sequencing of the exon encoding PR1 showed that colony inhibition was not caused by polymorphic differences in proteinase 3 between effecters and targets. Analysis by flow cytometry showed that proteinase 3 was overexpressed in the leukemia targets compared with normal marrow targets (median channel fluorescence 1,399 v 298, P = .009). These results show that PR1-specific allogeneic T cells preferentially inhibit leukemic CFU-GM based on overexpression of proteinase 3, and that proteinase 3-specific CTL could be used for leukemia-specific adoptive immunotherapy.
引用
收藏
页码:2529 / 2534
页数:6
相关论文
共 17 条
[1]
BOON T, 1994, IMPORTANT ADV ONCOL, V10, P53
[2]
The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response [J].
Boussiotis, VA ;
Freeman, GJ ;
Gribben, JG ;
Nadler, LM .
IMMUNOLOGICAL REVIEWS, 1996, 153 :5-26
[3]
BROUWER E, 1994, CLIN EXP IMMUNOL, V98, P448
[4]
IMMUNOCYTOCHEMICAL AND FLOW CYTOMETRIC DETECTION OF PROTEINASE-3 (MYELOBLASTIN) IN NORMAL AND LEUKEMIC MYELOID CELLS [J].
DENGLER, R ;
MUNSTERMANN, U ;
ALBATRAN, S ;
HAUSNER, I ;
FADERL, S ;
NERL, C ;
EMMERICH, B .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (02) :250-257
[5]
EFFECT OF T-CELL DEPLETION AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS ON ENGRAFTMENT, RELAPSE, AND DISEASE-FREE SURVIVAL IN UNRELATED MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA [J].
DROBYSKI, WR ;
ASH, RC ;
CASPER, JT ;
MCAULIFFE, T ;
HOROWITZ, MM ;
LAWTON, C ;
KEEVER, C ;
BAXTERLOWE, LA ;
CAMITTA, B ;
GARBRECHT, F ;
PIETRYGA, D ;
HANSEN, R ;
CHITAMBAR, CR ;
ANDERSON, T ;
FLOMENBERG, N .
BLOOD, 1994, 83 (07) :1980-1987
[6]
Giralt Sergio A., 1996, Current Opinion in Oncology, V8, P96, DOI 10.1097/00001622-199603000-00004
[7]
Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide [J].
Hooijberg, E ;
Visseren, MJW ;
vandenBerk, PCM ;
Jellema, AP ;
Romeijn, P ;
Sein, JJ ;
vanderVoort, EIH ;
Hekman, A ;
Ossendorp, F ;
Melief, CJM .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (05) :346-356
[8]
T-cell recognition of self peptides as tumor rejection antigens [J].
Kawakami, Y ;
Rosenberg, SA .
IMMUNOLOGIC RESEARCH, 1996, 15 (03) :179-190
[9]
GRAFT-VERSUS-LEUKEMIA EFFECT OF DONOR LYMPHOCYTE TRANSFUSIONS IN MARROW GRAFTED PATIENTS [J].
KOLB, HJ ;
SCHATTENBERG, A ;
GOLDMAN, JM ;
HERTENSTEIN, B ;
JACOBSEN, N ;
ARCESE, W ;
LJUNGMAN, P ;
FERRANT, A ;
VERDONCK, L ;
NIEDERWIESER, D ;
VANRHEE, F ;
MITTERMUELLER, J ;
DEWITTE, T ;
HOLLER, E ;
ANSARI, H .
BLOOD, 1995, 86 (05) :2041-2050
[10]
ADOPTIVE IMMUNOTHERAPY EVALUATING ESCALATING DOSES OF DONOR LEUKOCYTES FOR RELAPSE OF CHRONIC MYELOID-LEUKEMIA AFTER BONE-MARROW TRANSPLANTATION - SEPARATION OF GRAFT-VERSUS-LEUKEMIA RESPONSES FROM GRAFT-VERSUS-HOST DISEASE [J].
MACKINNON, S ;
PAPADOPOULOS, EB ;
CARABASI, MH ;
REICH, L ;
COLLINS, NH ;
BOULAD, F ;
CASTROMALASPINA, H ;
CHILDS, BH ;
GILLIO, AP ;
KERNAN, NA ;
SMALL, TN ;
YOUNG, JW ;
OREILLY, RJ .
BLOOD, 1995, 86 (04) :1261-1268